INCY logo

Incyte Corp. (INCY)$97.16

Market Cap: 12.02 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Incyte Corp. (INCY).

HEALTHCARE
BIOTECHNOLOGY
DCF ready

Valuation

6.3x

EV/FCF, 15.8% FCF yield

Quality

24.9%

ROIC, 27.5% FCF margin

Growth

14.0%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 3.3x current ratio

Superinvestors

2

Top: Harry Burn (2.4%)

Strengths to research

  • Revenue compounded at 14.0% over five years.
  • Return on equity is strong at 24.9%.
  • Free cash flow margin is healthy at 27.5%.
  • Debt/equity looks manageable at 0.0x.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for INCY.

Grade B
71
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
INCY
Target
Incyte Corp.$12.0B15.2x6.3x24.9%14.0%27.5%N/A-1.9xN/A
BMRNBioMarin Pharmaceutical Inc.$11.9B30.1x14.6x5.7%11.6%22.5%N/A-2.7xN/A
MRNAModerna, Inc.$10.8B-6.5x-4.0x-32.6%19.3%-106.2%N/AN/AN/A
ROIVRoivant Sciences Ltd$8.3B-55.5x-9.0x-6.6%-19.1%-9183.5%N/AN/AN/A
TECHBio-Techne Corp.$7.9B104.8x30.1x3.8%10.5%21.0%64.8%-0.8xN/A
RPRXRoyalty Pharma plc$19.0B30.6x11.0x4.1%2.3%104.7%N/A5.3xN/A
HALOHalozyme Therapeutics$7.5B26.7x14.7x14.5%39.2%46.2%N/A4.2xN/A
BBIOBridgeBio Pharma Inc.$7.3B-18.3x-19.5xN/A127.4%-89.0%N/AN/AN/A
LEGNLegend Biotech Corp.$6.1BN/AN/AN/AN/AN/AN/AN/AN/A

Financial Charts

No financial data available for INCY (annual).

2 superinvestors own INCY

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Dodge & Cox

Dodge & Cox

12,252,356$1.2B0.63%0.0%
Harry Burn

Sound Shore

767,829$72M2.42%0.0%